Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
    Neurology. 2004 Dec 28;63(12):2413-5.

    Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects.

    Source

    Raymond Escourolle Neuropathology Laboratory, INSERM U360, Salpêtrière Hospital, 47, bd de l'Hôpital, 75651 Paris Cedex 13, France. haik@chups.jussieu.fr

    Abstract

    Quinacrine has been reported as an antiprion agent and proposed as an immediately applicable treatment for Creutzfeldt-Jakob disease (CJD). The authors report the results of an open compassionate procedure to which 32 CJD patients had access. In some genotypic subgroups, a slight but nonsignificant increase in survival was observed, likely due to biased inclusion of long-term surviving patients. There was no pathologic evidence of a beneficial effect of quinacrine treatment.

    Comment in

    PMID:
    15623716
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for HighWire

      Save items

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk